Personalization of venetoclax/venetoclax tablet treatment courses

Venetoclax/Venetoclax (Venetoclax), as a highly effective, precise, orally administered small molecule B-cell lymphoma 2 inhibitor, has been widely used in the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). These conditions cause a patient's blood production to be disrupted, as cancer cells invade the bone marrow space and prevent the production of healthy blood cells. Venekra helps patients restore normal hematopoietic function through its unique mechanism.

Given that each patient’s disease progression and drug response are different, treatment schedules are not set in stone. In general, treatment with Venekra usually requires several consecutive sessions. For patients with SLL or CLL, treatment cycles with venetoclax may last a full year. For patients with acute myeloid leukemia, treatment can continue as long as the doctor and patient agree that it is safe to continue taking venetoclax. It is important that patients have an in-depth discussion with their treating physician to determine the length of treatment that is best for them. This is because the patient's overall health, including age and performance status, will affect the adjustment of drug dosage and treatment cycle.

At the same time, in order to ensure the effectiveness of treatment, patients need to be evaluated regularly so that doctors can adjust treatment plans according to real-time changes in their condition. The evaluation includes observing improvement in symptoms, changes in blood test indicators, and possible drug side effects. Therefore, determining the course of treatment is a flexible process that requires close communication between doctors and patients in order to make timely adjustments according to the actual situation.